Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel
This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation
therapy to see how well it works compared with antiandrogen therapy and radiation therapy
alone in treating patients with prostate cancer that has been removed by surgery. Androgen
can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen
made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink
tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or
without docetaxel after surgery may kill any remaining tumor cells.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.